Novavax, a U.S.-based vaccine manufacturer, announced on Wednesday the sale of its Czech Republic production facility to Novo Nordisk, the maker of Wegovy, for $200 million. The proceeds will support Novavax’s efforts to prioritize its vaccine pipeline and strengthen its core business. The sale aligns with the company’s ongoing strategy to streamline operations and focus on vaccine development. This move follows a recent $1.2 billion licensing agreement with French pharmaceutical giant Sanofi, which also acquired nearly a 5% stake in
